The art and science of non-invasive ventilation

Miquel Ferrer

Department of Pneumology, Thorax Institute, Hospital Clinic - Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
Centro de Investigaciones biomédicas En Red-Enfermedades Respiratorias (CibeRes CB06/06/0028)-IS-CIII

Address for correspondence:
Miquel Ferrer, MD, PhD
Senior Consultant
RICU, Department of Pneumology
Hospital Clinic, IDIBAPS
Villarroel 170
08036 Barcelona, Spain
Phone/Fax: +34 93 227 55 49
E-mail: miferrer@clinic.ub.es

Summary

Non-invasive ventilation (NIV) is one of the most relevant recent advances in the management of patients with severe acute respiratory failure (ARF). NIV is considered a standard of care for the management of hypercapnic ARF in patients with acute exacerbation of chronic obstructive pulmonary disease. With an appropriate selection of patients, NIV can reduce the need for invasive mechanical ventilation, mortality and length of stay. Patients with severe hypoxemic ARF have in general a lower likelihood to need tracheal intubation when NIV as a support for ARF is added to the standard medical treatment. However, the effects of NIV on mortality are less evident, and the heterogeneity of the different published studies suggests that the efficacy may be different among different populations. The optimal time for intubation after NIV failure remains a challenging issue due to increasing evidences on the relationship between delayed intubation and excess mortality in these populations. In intubated patients with pre-existing lung disease, the use of NIV in order to advance extubation during difficult and prolonged weaning can result in reduced periods of endotracheal intubation, complication rates and improved survival. Moreover, NIV immediately after extubation is effective in avoiding respiratory failure after extubation and improving survival in patients at risk for this complication, particularly those with chronic respiratory disorders, cardiac co-morbidity, and hypercapnic respiratory failure.

KEY WORDS: non-invasive ventilation, acute respiratory failure, weaning, hypoxemic respiratory failure, hypercapnic respiratory failure.

Introduction

Non-invasive ventilation (NIV) is one of the most relevant recent advances in the management of patients with severe acute respiratory failure (ARF). Non-invasive ventilation is ventilatory support through the upper airways of patients with an interface, usually a mask; therefore, tracheal intubation or a tracheostomy is not needed. The benefits of NIV appear to be the consequence of avoiding tracheal intubation and the associated morbidity and mortality (1, 2). There are several potential advantages for the use of NIV. Some patients can be managed out of an intensive care unit (ICU), a particularly stressful environment, with additional benefits in reducing the occupation of ICU beds and related costs. Ventilatory support can be intermittent and therefore withdrawal of NIV can be gradual. These patients can cooperate in respiratory therapy; they can receive nebulised therapy, expectorate and communicate with staff and their relatives. However, there are limitations for NIV. Unnecessary delay in intubation of those patients who fail with NIV treatment is associated with worse outcome (3). Some patients do not tolerate the mask due to claustrophobia or other causes, and nasal bridge skin breakdown can occur and difficult the use of NIV.

Non-invasive ventilation is now considered as a first-line intervention in patients with severe exacerbation of COPD and hypercapnic respiratory failure, and those affected of acute cardiogenic pulmonary oedema.
as advancing extubation in patients with difficult or prolonged weaning and in the management or prevention of post-extubation respiratory failure. Conversely, the efficacy of NIV in patients with different types of hypoxemic ARF is less evident from controlled clinical trials (9), with controversial results when all these trials are analysed together. Robust randomised clinical trials (RCT) are scarce, hence explaining why absence of specific recommendations often predominates in the evidence-based guidelines (10).

This review article will focus on the use of NIV in 3 different conditions: 1) COPD exacerbations and other causes of hypercapnic ARF; 2) patients with hypoxemic ARF; and 3) withdrawal of IMV.

Non-invasive ventilation in COPD exacerbations and other causes of hypercapnic acute respiratory failure

Chronic obstructive pulmonary disease exacerbation is one of the most frequent causes of hospital admission from emergency rooms (11); the majority of patients with advanced COPD may require hospital admission (12). Exacerbations are important events during the natural history of the disease (13), with worsening of lung function and health related quality of life (14). A COPD exacerbation that needs hospital admission is associated with poor outcome, with 34% readmission rate and 14% mortality rate after 3 months (15). Non-invasive ventilation can be implemented in different settings. Hypercapnic ARF secondary to COPD exacerbation is the best established indication for NIV. The majority of contraindications for NIV previously described were considered exclusion criteria in controlled clinical trials; since there are no evidences for associated complications, they should be considered as relative rather than absolute. Settings that require special attention during NIV include recent gastrointestinal or upper airway surgery, inability to protect the airways, hemodynamic instability, decreased consciousness, vomiting, intestinal occlusion, undrained pneumothorax, and confusion and agitation states. Recent studies have shown that NIV can be successfully used in patients with hypercapnic coma (16) and after upper gastrointestinal surgery (17). The clinical setting is also important; if NIV is the ceiling of treatment and therefore the only treatment option, a relative contraindication can be accepted, whereas it may not be if intubation is considered appropriate. It is better, therefore, to consider these as situations requiring special care rather than contraindications per se. There are some situations, however, in which NIV is almost never appropriate, such as severe fixed upper airway obstruction requiring tracheostomy, and severe facial burns or trauma or anything that renders it impossible to fix an interface.

Non-invasive ventilation is complementary rather than an alternative to IMV, an intermediate level of support between no ventilatory support and IMV. The primary aim should be in general preventing progression of ARF to the point at which patients will require intubation.

Intensive care units

The first RCT on the use of NIV in COPD exacerbations was conducted in an ICU (18). These patients had severe respiratory acidosis before inclusion into the study. Compared with standard medical treatment, the use of NIV decreased dramatically the need for intubation, with less incidence of complications, shorter hospital stay and lower hospital mortality. The benefits of NIV have been confirmed in several controlled trials in different countries (4). Moreover, no clinical study demonstrated that NIV is inferior to standard medical treatment.

In all these studies, patients deemed to need immediate intubation were excluded. A subsequent study on patients with COPD exacerbation that had failed standard medical treatment compared the use of NIV with immediate intubation (19). Therefore, these patients were substantially more severe that those included in previous studies, assessed by a mean arterial pH around 7.20 before randomisation. This study showed that NIV could avoid intubation in 48% patients and did not provide worse ventilatory support than IMV. Patients with good response to NIV had shorter ICU stay and better outcomes during the year after the hospitalisation, with less readmission and less need of long-term oxygen therapy.

A more recent study compared 543 patients with COPD exacerbation and 173 patients with obesity-hypoventilation syndrome, admitted to an ICU for an episode of hypercapnic ARF. Despite their baseline severity of respiratory acidaemia, with a mean arterial pH 7.22, NIV was highly effective, with failure rates of 11% and 6% for patients with COPD and obesity-hypoventilation syndrome, respectively (20).

Conventional wards

Based on the evidence of successful use of NIV in the ICU, the lack of need for pharmacologic sedation, and because NIV can be used earlier in the evolution of ARF before patients are considered to need intubation, several studies have assessed the use of NIV in conventional wards. The most relevant was a multicentre trial on COPD exacerbation that confirmed the efficacy of NIV in this setting (21). The early use of NIV together with standard treatment decreased the NIV failure rate and the hospital mortality compared with standard treatment alone. A subgroup analysis in patients with more severe acidaemia, with baseline arterial pH<7.30, showed...
no clinical benefits with an outcome worse than expected, suggesting that these patients with more severe acidosis should be managed in facilities with closed control and monitoring than that available in conventional wards. Conversely, in patients with very mild acidosis or no acidosis, NIV has not demonstrated any clinical benefit (22).

**Emergency room**

The emergency room is the first point of contact for many patients. In this setting, the main priority is optimizing medical treatment. Around 20% patients with COPD exacerbation have initial respiratory acidosis, and in 20% of them arterial pH can be normalised by simply optimizing medical treatment (23), since hyperoxygenation is a common cause of hypercapnic acidosis. An Australian study showed a higher mortality rate in COPD patients that received uncontrolled oxygen therapy in the ambulance compared with those in whom oxygen was titrated to achieve an arterial O2 saturation (SaO2) of 88-92% (24). The use of high-flow oxygen contributes to increase the hospital length of stay, ICU admission and the need for NIV when patients achieve higher levels of SaO2 (25). Therefore, patients with acidosis at arrival to the emergency room should receive oxygen with the aim to achieve SaO2 between 88 and 92% (26), in addition to medical treatment, including nebulised bronchodilators, steroids and antibiotics if indicated. If respiratory acidosis persists, NIV may be initiated in the emergency room with acceptable results as shown in a prospective study (27).

Figure 1 shows a simple algorithm proposed for taking decisions regarding NIV in COPD exacerbations.

**Non-invasive ventilation in hypoxemic acute respiratory failure**

The first problem in addressing patients with hypoxemic ARF is the heterogeneity of this condition. Studies assessing the outcome of patients with hypoxemic ARF treated with NIV in the ICU identified up to 9 different groups of patients, with substantial differences among them in the outcomes (Figure 2) (28). Moreover, a majority of clinical trials that assessed the efficacy of NIV in patients with hypoxemic ARF have studied mixed populations. The role of NIV in the management of patients with hypoxemic ARF from clinical trials with mixed and specific populations of patients will be discussed.

**The use of high-flow uncontrolled oxygen in ambulance for COPD exacerbation contributes to worsen outcomes compared to oxygen titration to achieve an arterial O2 saturation of 88-92%**.

---

**Figure 1 - Proposed algorithm for the institution of non-invasive ventilation in hypercapnic acute respiratory failure.**
Severe community-acquired pneumonia
The main objective of NIV in severe ARF is overcoming the acute episode without the need for intubation. However, pneumonia in patients treated with NIV is persistently associated with poor outcome in the literature, compared with other causes of ARF, both in patients with COPD exacerbations (29) and in hypoxemic ARF (28). More recent studies have confirmed high failure rates in patients with pneumonia and severe ARF (27, 30-32).

The only prospective randomised clinical trial (RCT) in the literature that compared conventional treatment with or without NIV demonstrated that patients who had received NIV together with conventional treatment had lower rate of tracheal intubation and a shorter stay in the intermediate-care unit than those who received conventional treatment only, although the length of hospital stay and hospital mortality were similar between both groups (33). This study also showed in a subset analysis that the significant benefits of NIV occurred in patients with COPD and hypercapnic respiratory failure only; this subset of patients had also a lower mortality after two months. In contrast, patients without COPD nor hypercapnic respiratory failure did not benefit from NIV. The better outcomes of NIV in patients with pneumonia and COPD and hypercapnia, compared with those with “de novo” ARF, have been recently highlighted (34).

Acute respiratory distress syndrome
Most observational studies and subgroup analyses of RCT show that patients with acute respiratory distress syndrome (ARDS) are among those with the worst outcome when they receive NIV as a support measure for severe hypoxemic ARF, with high rates of NIV failure (28, 30, 35-38), and limited efficacy of NIV. The severity of arterial hypoxemia and the frequent impairment of pulmonary mechanics in these patients may explain the high intubation rate showed in several studies, regardless of NIV use or not. The only published RCT on the use of NIV was conducted in patients with mild ARDS according to the new Berlin definition (39). This study showed a decrease in the intubation rate and development of organ system dysfunctions, and a trend to decrease in-hospital mortality, with the use of NIV (40). One trial in more severe ARDS reported a significantly lower intubation rate with NIV in 84 patients with ARDS, but it was pub-
A prospective observational study in 54 patients with acute lung injury who received NIV found that shock, metabolic acidosis and profound hypoxemia predicted NIV failure (30). In this study, the observed mortality of patients who failed NIV was higher than that predicted by severity scores, suggesting that NIV should tried very cautiously, or not at all in patients with predictors of NIV failure, and particularly discouraged the use of NIV in those patients presenting with shock and metabolic acidosis. Another prospective multicenter cohort study showed that NIV as a first-line intervention improved hypoxemia and avoided intubation in 54% patients with early ARDS (42). In this study, higher severity scores and failure to improve hypoxemia after 1 hour of NIV were independently associated with NIV failure. This study suggested that, in absence of criteria for immediate intubation, NIV could be tried in expert centres for patients with ARDS, avoiding the use in patients with predicted high mortality. The authors recommended a close monitoring of arterial oxygenation and to proceed to rapid intubation when oxygenation in not rapidly improved after initiation of NIV. Overall, the risk-benefit ratio of NIV is still not defined in ARDS and current evidence does not support the routine use of NIV in these patients.

Other causes of severe hypoxemic acute respiratory failure

An important part of the first published series assessing the efficacy of NIV in patients with hypoxemic ARF included patients with different causes of ARF. These series could not establish the efficacy of NIV in this subset of patients and showed disparate results, mainly because of the own heterogeneity of hypoxemic ARF, since patients with CPO, ARDS and trauma were also included (43). Moreover, some of these initial studies observed a limited efficacy of NIV in patients with hypoxemic ARF of different origin, compared to patients with hypercapnic respiratory failure (44). The first RCT specifically conducted in severely hypoxemic patients compared NIV with tracheal intubation in 64 with predefined criteria for initiating ventilatory support (45). Among patients who received NIV, only 31% required intubation. Likewise, the improvement in arterial oxygenation after the protocol was implemented was similar in patients from both groups, and the incidence of severe infectious complications was lower in patients who received NIV, with a trend to a lower ICU mortality and length of stay, compared with those who were initially intubated. A more recent trial in patients with chest trauma re-

Figure 3 - Time-course evolution (mean±SEM) of arterial hypoxemia, as assessed by the PaO₂/FiO₂ ratio (panel A), and respiratory frequency (panel B), in the two groups. Both variables improved with time in the two groups. Asterisks denote significant differences between the two groups at individual time-points. After Bonferroni correction, the improvement of the two variables was significantly greater in the NIV group after 3-4 hours of randomization, and remained significantly greater 24 and 6-8 h after randomization for PaO₂/FiO₂ ratio and respiratory frequency, respectively. The table below the graph denotes the number of patients remaining under study at each time-point in the two groups. The time-course decrease of patients corresponds to those meeting criteria to terminate the protocol. Adapted from (35).
remaining hypoxic despite regional anaesthesia showed that NIV reduced intubation compared with oxygen therapy in severe thoracic trauma related hypoxemia, with reduced length of hospital stay. However, mortality in this study was the same in both groups (46). In contrast, CPAP with face mask in patients with severe hypoxemic ARF improved hypoxemia, compared with oxygen therapy, but did not decrease the needs for tracheal intubation, hospital mortality and ICU length of stay (Figure 4) (47).

Physiologic effects of non-invasive ventilation in patients with hypoxemic acute respiratory failure

The different clinical efficacy between NIV and CPAP may be explained by the results of a physiological study performed in 10 patients with severe hypoxemic ARF of different origin (48). Compared with spontaneous breathing, the respiratory frequency, the work of breathing and the respiratory drive improved only with NIV, whilst CPAP was more effective in improving. Since the most frequent indication for intubation in patients with hypoxemic ARF is exhaustion (35), it is necessary to combine NIV with PEEP in order to decrease the inspiratory effort, whilst CPAP improves arterial oxygenation but does not unload the respiratory muscles (Figure 5) (48).

Failure of non-invasive ventilation: when to intubate?

Concerns have been raised due to the high mortality rate of patients with hypoxemic ARF who fail NIV treatment (28). Particularly, failure of NIV was associated with ICU mortality in patients with hypoxemic ARF and without previous cardiac or respiratory disease ("de novo" ARF), but not in patients with acute-on-chronic respiratory failure or CPO in a prospective multicenter study (3). The possibility that unnecessary delay of intubation results in excess mortality in patients with acute lung injury was also highlighted in another prospective study that showed an actual mortality of patients intubated after NIV failure higher than mortality predicted by severity scores (30). However, these comparisons may be misleading, since severity scores often underestimate hospital mortality in ICU patients (49, 50). A more recent prospective study on the use of NIV in patients with CAP and severe ARF found for the first time a consistent association between delayed intubation and increased mortality in patients with CAP and "de novo" ARF (34). In this study, a longer time on NIV before intubation was associated with less survival, even after adjustment for potential confounders such as severity scores and shock. A longer duration of NIV before intubation was not related with severity of patients at admission in this study. Therefore, this excess of mortality was attributed to delayed intubation rather than a more severely-ill selected population. By contrast, no relationship was found between delayed intubation and mortality in patients with CAP and previous cardiac or respiratory disease from this study (34).

In summary the RCTs of the literature suggest that patients with severe hypoxemic ARF have in general a lower likelihood to need tracheal intubation when NIV as a support for respiratory failure is added to the standard medical treatment. However, the effects of NIV on mortality are less evident, and the heterogeneity of the different published studies suggests that the optimal time for intubation after NIV failure remains a challenging issue due to increasing evidences on the relationship between delayed intubation and excess mortality in NIV failure patients.
efficacy may be different among different populations. The optimal time for intubation after NIV failure remains a challenging issue due to increasing evidences on the relationship between delayed intubation and excess mortality in these populations.

Non-invasive ventilation in withdrawal from mechanical ventilation

An International Consensus Conference on weaning from MV (51) proposed a new classification based on the difficulty and duration of the weaning period: 1) simple weaning; 2) difficult weaning; and 3) prolonged weaning. Patients with chronic airflow obstruction and difficult or prolonged weaning are at increased risk for prolonged IMV. Non-invasive ventilation has been used in different indications during withdrawal of mechanical ventilation: 1) to advance extubation in patients with difficult or prolonged weaning; 2) to avoid re-intubation in patients who have developed post-extubation respiratory failure; and 3) to prevent the development of post-extubation respiratory failure. The role of NIV in all these indications will be reviewed.

Pathophysiologic mechanisms of difficult and prolonged weaning (Table 1)

Patients with unsuccessful weaning from mechanical ventilation are likely to develop during a spontaneous breathing trial a rapid and shallow breathing pattern (52), with progressive worsening of dynamic lung elastance, intrinsic PEEP (PEEPi), inspiratory resistance, and work of breathing (53). All these changes are not present when patients successfully tolerate a spontaneous breathing trial. In COPD patients, an inappropriate cardiovascular response to the switch from positive-pressure ventilation to spontaneous breathing with left ventricular dysfunction and increased pulmonary artery occlusion pressure may also occur during weaning failure (54, 55), with decreased mixed venous oxygen saturation (56), reflecting the inability of the cardiovascular system to compensate the increased systemic oxygen demands when spontaneous breathing is instituted. Conversely, in successfully weaned patients, mixed venous oxygen tension or saturation was shown to remain unchanged or increased during spontaneous breathing, compared with positive pressure ventilation (56-58).

Figure 5 - Average changes in respiratory variables [respiratory frequency, arterial hypoxemia, assessed by the arterial oxygen tension to inspired oxygen fraction ratio, work of breathing, assessed by the pressure-time product of the diaphragm (PTPdi), and the respiratory drive, assessed by the occlusion pressure (P0.1)] comparing the initial and final values during spontaneous breathing with the three ventilatory modalities: CPAP 10 cmH2O, pressure-support ventilation (PSV) 10 cmH2O with PEEP 10 cmH2O, and PSV 15 cmH2O with PEEP 5 cmH2O. Asterisks denote significant differences between initial values and the specific ventilatory modality. Adapted from (48).
The art and science of non-invasive ventilation

Table 1 - Pathophysiologic bases of weaning failure during transition from positive-pressure ventilation to spontaneous breathing.

- Rapid and shallow breathing pattern
- Increased workload of the respiratory muscles:
  - Increased PEEPi
  - Increased elastance and resistance of the respiratory system
  - Increased work of breathing
  - Increased effective inspiratory impedance
  - Increased load/capacity balance
- Inappropriate cardiovascular response
  - Increased venous return to right ventricle
  - Increased negative deflections in intrathoracic pressure
  - Increased left ventricular afterload
- Fall of mixed venous P\(\text{VO}_2\) and S\(\text{O}_2\)
- Impaired neurological status

Definitions of abbreviations: PEEPi = intrinsic positive end-expiratory pressure; P\(\text{VO}_2\) = mixed venous oxygen tension; S\(\text{O}_2\) = mixed venous oxygen saturation.

Rationale for the use of non-invasive ventilation during difficult and prolonged weaning (Table 2)

In COPD patients, the rationale for using NIV in facilitating weaning may be related to the ability of NIV to reduce the work of breathing (59), with an additive effect of both positive pressure ventilation and external PEEP. The short-term improvement of hypoxemia and hypercapnia with NIV in these patients appear to be related to increased alveolar ventilation secondary to attainment of a slower and deeper breathing pattern, with no changes in the ventilation-perfusion mismatch (60). The same beneficial effects have been demonstrated in ventilator-dependent patients with chronic respiratory disorders, with similar efficacy of pressure-support ventilation delivered through the endotracheal tube and non-invasively after extubation in reducing the work of breathing and improving arterial blood gases and respiratory pattern (61).

Table 2 - Physiologic effects of non-invasive positive-pressure ventilation.

- Effect on respiratory mechanics
  - Decrease negative deflections of intrathoracic pressure
  - Decreased work of breathing
  - Additive effects of positive pressure ventilation and external PEEP
- Effects on gas exchange
  - Improvement of hypoxemia and hypercapnia secondary to slower and deeper breathing pattern
  - No effects on ventilation-perfusion mismatch

Definitions of abbreviations: PEEP = positive end-expiratory pressure.

The use of non-invasive ventilation during difficult and prolonged weaning

Shortening weaning and avoiding re-intubation should be the primary end-point when NIV is indicated in patients with unsuccessful weaning from mechanical ventilation, as stated in an International Consensus Conference (62).

A RCT conducted in a selected group of 50 intubated COPD patients with severe hypercapnic respiratory failure who had recovered from an exacerbation within 48 h of mechanical ventilation but had failed a spontaneous breathing trial with a T-piece showed that early extubation with NIV support resulted in shorter duration of mechanical ventilation and ICU stay, a lower incidence of nosocomial pneumonia and improved survival (63).

In a similar population of 33 intubated patients with acute-on-chronic respiratory failure after a single weaning trial failure with hypercapnic respiratory failure, extubation with NIV permitted a reduction of the endotracheal mechanical ventilation period of 3 days in average (64).

The effect of NIV during prolonged weaning was assessed in 43 mixed patients, predominantly with chronic respiratory disorders, that had failed a spontaneous breathing trial for 3 consecutive days (65). In this study, advancing extubation with NIV resulted again in a decreased duration of mechanical ventilation and stay, lower incidence of incidence of nosocomial pneumonia and septic shock/multiple organ failure, less need of tracheotomy to facilitate weaning, and improvement in survival.

The use of mechanically-assisted cough in addition to NIV has been recently described in 157 consecutive weanable” intubated patients with neuromuscular disease (66). This study showed that continuous volume-cycled NIV via oral interfaces and masks and mechanically-assisted cough permitted safe extubation in 95% of cases after the first attempt, with additional success on subsequent attempts in some additional patients.

A systematic review and meta-analysis on the use of NIV to wean critically-ill adult patients off mechanical ventilation identified several additional RCTs published or presented as abstracts (67). This study showed a consistent positive effect of NIV on mortality and ventilator-associated pneumonia, though the net clinical benefits remain to be fully elucidated (Table 3). This study also recommended that NIV should preferentially be used in patients with COPD in a highly monitored environment. This emphasis in COPD as the population most prone to benefit from NIV in facilitating difficult and prolonged weaning has been recently suggested (68).

However, all these studies, and the conclusions drawn from them, are related to selected populations of patients with underlying chronic airflow obstruction and
hypercapnic respiratory failure, hemodynamic stability, normal consciousness, absence of fever, and preserved cough reflex. Moreover, the 12 RCTs identified in a recent systematic review included a total of 530 patients; however, only 3 of these trials, with 126 patients included, were published in high quartile peer-review journals (67).

Because it must be distinguished between dependence from the ventilator and from the endotracheal intubation, when the process of mechanical ventilation withdrawal is initiated, it is necessary to evaluate: 1) the need of ventilatory support with a spontaneous breathing trial; and 2) whether the artificial airway is needed or not. The beneficial effects of NIV as a weaning supporting technique can be expected only when an initial weaning attempt has failed (ventilator dependence) but there is no need for an artificial airway. The main reasons for failure of NIV are the lack of cooperation, excessive secretions, severe strength-load imbalance and hemodynamic instability, which can be corrected by protection of the airways and proper medical therapy. In general, it is estimated that around 30-35% of intubated COPD patients with hypercapnic respiratory failure needing progressive withdrawal of mechanical ventilation are not likely to benefit from NIV, but large-scale studies are needed to confirm these estimations.

Respiratory failure after extubation
Re-intubation, which occurs in 6 to 23% cases within 48 to 72 hours after planned extubation (69-71), is a relevant consequence of respiratory failure after extubation (72). Although the need for re-intubation may be a marker of increased severity of illness, this is an independent risk factor for nosocomial pneumonia (73), and mortality and increased hospital stay (69). Therefore, in addition to an accurate prediction of extubation outcome, strategies for preventing the development of respiratory failure after extubation and subsequent re-intubation are needed.

Non-invasive ventilation in the management of respiratory failure after extubation
The clinical benefits of NIV in the management of patients who have been extubated but have developed respiratory failure after extubation are not encouraging. Two RCTs on the use of NIV in the treatment of respiratory failure after extubation did not show benefits from NIV in reducing re-intubation (72,74). The first trial selected 81 patients with different underlying diseases, and did not find any benefit from NIV in terms of re-intubation, duration of mechanical ventilation and stay, and survival (74). More recently, a multi-centre international RCT in 221 patients who develop respiratory failure after extubation found again no benefits for NIV in reducing re-intubation and length of stay (72). The striking point of this study was a higher ICU mortality in patients treated with NIV, attributed to a longer period of time from extubation to re-intubation in patients treated with NIV, which is an independent risk factor for mortality in re-intubated patients (75). In both trials, the proportion of COPD patients was low, 10% and 11%.

If the use of NIV after extubation prolongs time to re-intubation, then NIV may become an independent risk factor for mortality in re-intubated patients.

Table 3 - Summary estimates of the effect of non-invasive ventilation to wean critically ill adults off invasive ventilation. Adapted from (67).

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Summary estimate (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality *</td>
<td>0.55 (0.38 to 0.79)</td>
<td>0.001</td>
</tr>
<tr>
<td>VAP *</td>
<td>0.29 (0.19 to 0.45)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Weaning failures *</td>
<td>0.72 (0.37 to 1.42)</td>
<td>0.34</td>
</tr>
<tr>
<td>Length of stay:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intensive care †</td>
<td>-6.3 (-8.8 to -3.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Hospital †</td>
<td>-7.2 (-10.8 to -3.6)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Duration of mechanical ventilation:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total †</td>
<td>-5.6 (-9.5 to -1.8)</td>
<td>0.004</td>
</tr>
<tr>
<td>Related to weaning †</td>
<td>-0.9 (-3.2 to 1.4)</td>
<td>0.42</td>
</tr>
<tr>
<td>Endotracheal †</td>
<td>-7.8 (-11.3 to -4.3)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Adverse effects:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Re-intubation *</td>
<td>0.73 (0.40 to 1.34)</td>
<td>0.31</td>
</tr>
<tr>
<td>Tracheostomy *</td>
<td>0.16 (0.04 to 0.75)</td>
<td>0.020</td>
</tr>
<tr>
<td>Arrhythmia *</td>
<td>1.05 (0.17 to 6.67)</td>
<td>0.96</td>
</tr>
</tbody>
</table>

**Abbreviations:** VAP=ventilator associated pneumonia; CI = confidence interval.

*Relative risk. † Weighted mean difference.
Non-invasive ventilation in the prevention of respiratory failure after extubation

Since NIV seems not effective to avert re-intubation once patients have developed respiratory failure after extubation, a strategy based on the early use of NIV during the initial periods after extubation in order to avert respiratory failure after extubation in patients at risk for this complication seems more appropriate. Several RCTs have used this approach with favourable results. In selected patients at increased risk to develop respiratory failure after extubation, the early use of NIV after a successful weaning trial was compared with a conventional approach using oxygen therapy (76, 77). In both studies, the use of NIV resulted in decreased incidence of extubation failure and reintubation, with a strong association between the need for re-intubation and mortality. A subgroup analysis in one of these studies found in improvement in survival only in patients with hypercapnia during the spontaneous breathing trial (77). After these findings, the same group conducted a new RCT specifically in patients with chronic respiratory disorders and hypercapnia during a successful spontaneous breathing trial, with the same study design (78). The results from this study confirm again that the use of NIV immediately after extubation results in decreased incidence of respiratory failure after extubation and improved survival. The benefits of NIV in the prevention of respiratory failure after extubation were also documented in severely obese patients in a case-control study (79). In this study, the benefits in survival were also restricted in hypercapnic patients only. More recently, a multicentre RCT in difficult-to-wean patients with chronic hypercapnic respiratory failure investigated the effectiveness of NIV as an early weaning and extubation technique (80). The weaning failure rate in this study was significantly lower for patients extubated with NIV, compared with patients extubated without ventilatory support or those who remained intubated with a conventional weaning.

In summary, NIV is consistently effective in advancing extubation and decreasing complications associated with prolonged invasive ventilation in intubated patients with chronic respiratory disorders and difficult or prolonged weaning. There are also evidences on the efficacy of early use of NIV in preventing extubation failure and improving outcome in patients with chronic respiratory or cardiac diseases who present with hypercapnic respiratory failure during a spontaneous breathing trial. A very recent report has confirmed that such population is at high risk for extubation failure and subsequent pneumonia and death (81). A schematic representation of the application of NIV during the different phases of ventilator withdrawal is shown in Figure 6.

References


Figure 6 - Schematic representation of the application of non-invasive ventilation (NIV) during the different phases of ventilator withdrawal. SBT = spontaneous breathing trial; COPD = chronic obstructive pulmonary disease. Adapted from (68).
M. Ferrer

The art and science of non-invasive ventilation


